A phase 1b study of a nonopioid, nerve-ablating painkiller from Sorrento Therapeutics showed rapid relief of osteoarthritic knee pain that lasted for nearly three months at its lowest dose, prompting the company to begin planning pivotal studies for this year.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,